Rhythm Pharmaceuticals
Price & Volume
Stats
See more52W Range | $60.70-$122.20 |
Market Cap | $6.5B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $217.1M |
Revenue Growth (YoY) | 83.8% |
Gross Profit (12 Mos) | $194.1M |
Diluted EPS | -$3.13 |
News
See moreYahoo Finance • yesterday
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Yahoo Finance • 3 days ago
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Yahoo Finance • 4 days ago
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Yahoo Finance • last month
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
About
CEO | Dr. David P. Meeker M.D. |
CFO | Mr. Hunter C. Smith M.B.A. |
Address | 222 Berkeley Street, Boston, MA, United States, 02116 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 414 |